Financier Cathal Friel is a familiar figure in Irish business. Over the years he has worked in finance, oil and gas, technology and media, but it is in his current project, Open Orphan, where he appears to have caught lightning in a bottle.
Open Orphan was only set up in 2017 as a niche pharmaceutical services company.
Two years later, Friel engineered a reverse takeover of stock market Venn Life Sciences – struggling at the time but already established on the Irish stock exchange and able to tap fresh investment.
Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data).